# Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

> **NCT03572647** · PHASE1 · COMPLETED · sponsor: **Azidus Brasil** · enrollment: 40 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Eritromax
- **DRUG:** Eprex

## Key facts

- **NCT ID:** NCT03572647
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2012-11
- **Final completion:** 2013-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572647, "Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03572647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*